Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Change in Account Payables (2016 - 2025)

Collegium Pharmaceutical has reported Change in Account Payables over the past 10 years, most recently at $3.0 million for Q4 2025.

  • Quarterly results put Change in Account Payables at $3.0 million for Q4 2025, up 275.93% from a year ago — trailing twelve months through Dec 2025 was $6.7 million (up 159.57% YoY), and the annual figure for FY2025 was $6.7 million, up 159.57%.
  • Change in Account Payables for Q4 2025 was $3.0 million at Collegium Pharmaceutical, up from -$3.3 million in the prior quarter.
  • Over the last five years, Change in Account Payables for COLL hit a ceiling of $13.9 million in Q1 2025 and a floor of -$7.0 million in Q2 2025.
  • Median Change in Account Payables over the past 5 years was -$537500.0 (2023), compared with a mean of -$301650.0.
  • Biggest five-year swings in Change in Account Payables: plummeted 1150.0% in 2021 and later surged 648.86% in 2025.
  • Collegium Pharmaceutical's Change in Account Payables stood at -$3.5 million in 2021, then fell by 17.0% to -$4.1 million in 2022, then surged by 219.6% to $5.0 million in 2023, then tumbled by 83.65% to $810000.0 in 2024, then soared by 275.93% to $3.0 million in 2025.
  • The last three reported values for Change in Account Payables were $3.0 million (Q4 2025), -$3.3 million (Q3 2025), and -$7.0 million (Q2 2025) per Business Quant data.